Alternative capsid strategies for targeting recombinant AAV gene therapy

The advent of new serotypes of adeno-associated viruses (AAV), has expanded the tissue tropism and allowed clinically relevant numbers of cells to be transduced by rAAV vectors. The two most significant obstacles in the way of future gene therapies with AAV vectors are tissue/target cell specificity...

Full description

Saved in:
Bibliographic Details
Published in:Gene therapy and regulation 2004, Vol.2 (2), p.139-148
Main Authors: Flotte, Terence, Loiler, Scott
Format: Article
Language:English
Subjects:
ADENO-ASSOCIATED VIRUS
DIABETES
GENE THERAPY
TARGETING
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The advent of new serotypes of adeno-associated viruses (AAV), has expanded the tissue tropism and allowed clinically relevant numbers of cells to be transduced by rAAV vectors. The two most significant obstacles in the way of future gene therapies with AAV vectors are tissue/target cell specificity and sitel-specific integration. Other reviews contained in this issue will look at advances in site-specific integration. This review will focus on the latest developments in AAV vector tropism and tissue/target cell specificity.
ISSN:1388-9532
1568-5586
DOI:10.1163/156855803322664628